Yang Lei, Wang Xingcheng, Wang Binsheng, Chao Peng, Li Debang, Chai Chen
Department of General Surgery, First Hospital of Lanzhou University.
The First Clinical College of Lanzhou University, Lanzhou University, Lanzhou, Gansu, P.R. China.
Medicine (Baltimore). 2018 Dec;97(49):e12789. doi: 10.1097/MD.0000000000012789.
To evaluate the clinical outcomes of S-1 plus cisplatin (SC) for the treatment of patients with advanced gastric cancer (AGC).
A systematic literature search was conducted by searching PubMed, the Cochrane Library, Embase, China Biology Medicine disc (CBMdisc), China National Knowledge Infrastructure (CNKI), and WanFang Database, for all year up to January 2017. Pooled analyses of overall survival (OS), progress-free survival rates, and adverse events were performed.
A total of 8 random controlled trails (RCTs) consisting of 2699 patients with AGC were selected and included in this meta-analysis. The results of our meta-analysis showed that AGC patients who treated with SC regimen receive a similar OS (HR = 1.01, 95%CI: 0.86-1.18, P = .928), PFS (HR = 0.89, 95%CI: 0.72-1.09, P = .263), and overall response rate (HR = 0.88, 95%CI: 0.70-1.11, P = .283). However, SC regimen may increase the risk of 1 to 2 grade (OR = 1.128, 95%CI: 1.075-1.184, P = .000) and 3 to 4 grade (OR = 1.24, 95%CI: 1.01-1.52, P = .039) adverse events.
SC chemotherapy showed no difference in survival compared with 5-FU- and S-1-based other therapy, but has a higher rate of adverse events compared with other chemotherapy regimens.
评估S-1联合顺铂（SC）治疗晚期胃癌（AGC）患者的临床疗效。
通过检索PubMed、Cochrane图书馆、Embase、中国生物医学文献数据库（CBMdisc）、中国知网（CNKI）和万方数据库，对截至2017年1月的所有年份进行系统文献检索。对总生存期（OS）、无进展生存率和不良事件进行汇总分析。
共选择8项随机对照试验（RCT），纳入2699例AGC患者进行该荟萃分析。荟萃分析结果显示，接受SC方案治疗的AGC患者的总生存期（HR = 1.01，95%CI：0.86 - 1.18，P = 0.928）、无进展生存期（HR =
